UBS Group’s Clovis Oncology, Inc. CLVS Stock Holding History

UBS Group’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-152,200	Closed	-$731K	–	9716
2020 Q4	$731K	Buy	152,200 +2,200	+1%	+$11.1K	﹤0.01%	4270
2020 Q3	$875K	Hold	150,000	–	–	﹤0.01%	3739
2020 Q2	$1.01M	Hold	150,000	–	–	﹤0.01%	3497
2020 Q1	$954K	Hold	150,000	–	–	﹤0.01%	3395
2019 Q4	$1.56M	Hold	150,000	–	–	﹤0.01%	3795
2019 Q3	$590K	Buy	+150,000	New	+$1.21M	﹤0.01%	4425
2019 Q2	–	Sell	-100,000	Closed	-$2.48M	–	8284
2019 Q1	$2.48M	Buy	+100,000	New	+$2.51M	﹤0.01%	2812

Other funds holding CLVS

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group's CLVS Position: Q4 2022 in Review

UBS Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 4,239 shares — an estimated $5K sold.

UBS Group first reported a position in CLVS in Q4 2014 and held it in 32 quarters. The position peaked at $14.8M in Q1 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

UBS Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
UBS Group sold 4,239 Clovis Oncology, Inc. shares in Q4 2022, an estimated $5K.
UBS Group first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 32 quarters.
UBS Group's Clovis Oncology, Inc. position peaked at $14.8M in Q1 2015.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.